Clinical Trials and Research
IERSurgery is now a site for the RELIEF Study.
The purpose of the study is to collect information about the use of the LINX device in patients who have previously undergone a Laparoscopic Sleeve Gastrectomy (LSG). Like other patients with a weak lower esophageal sphincter (LES), post-LSG patients may remain susceptible to gastroesophageal reflux disease (GERD) until the LES barrier function is restored. However, post-LSG patients have limited options for reflux control given their altered gastric anatomy which may not allow them to have standard surgical anti-reflux procedures like fundoplication. The safety and effectiveness of the LINX device has not been established in patients with a previous LSG.
If you have had a sleeve gastrectomy and suffer from reflux, please call 303-788-1636 and talk with Rachel, our research coordinator to learn more.
Click here to read the NECTAR Study.
LESS GERD Endostim Study
The EndoStim system is a new, minimally-invasive approach to treating gastroesophageal reflux disease (GERD) by neurostimulation. GERD occurs when stomach acid or other stomach contents flow back into the esophagus, often caused by a weak valve, or sphincter, between the esophagus and the stomach. The backwash (reflux) irritates the lining of the esophagus and causes GERD. The EndoStim system is designed to restore the function of this sphincter. The procedure is designed to be uniquely gentle – to keep your anatomy intact and reduce or avoid chances of gastro-intestinal side effects.
Most individuals with GERD are successfully treated with acid blocking medications called proton pump inhibitors (PPI), such as Nexium, Prevacid or Prilosec. However, nearly 30 percent of individuals on PPI medication continue to suffer from symptoms. If you are taking PPI medications every day but your symptoms do not completely go away, or if you experience side effects from the medication, you may be eligible for the LESS GERD trial.
ROARS (Registry of Outcomes from AntiReflux Surgery)
This registry collects information about standard antireflux surgical treatment options in everyday clinical practice to better understand the disease and develop better methods to treat it so we may improve patient care.
Now closed. We are the first site in the country and the only site in the Rocky Mountain region to start enrolling patients in the CALIBER study which is a randomized study look at the LINX device compared to taking reflux medications. We enrolled more than any other site in the country. Results to be published soon….
LINX with hiatal hernia
Institute of Esophageal and Reflux Surgery is now enrolling patients for this study.We are participating in a multi center study to look at the use of the LINX Reflux Management System in patients with moderate sized hiatal hernias. We are again the only site in the Rocky Mountain Region to be able to offer this study.
This is a randomized placebo controlled trial to look at the efficacy of the Esophyx device. This study is now closed. Click below to read the results.
This is an ongoing evaluation of patients that have had the Esophyx/TIF procedure to see how they are doing long term. This study is now closed.
LINX post market analysis
We are the only site in the Rocky Mountain Region that was asked to participate in a study to evaluate patients long term who have had the LINX device placed. This is a requirement by the FDA after approving the device for use. This study is now closed.
Prospective study- This is an ongoing study to evaluate all aspects of our care, from testing and diagnosis to outcomes of surgery. By carefully evaluating our data, we are able to improve outcomes, establish quality control, and publish our information.
To see all publications click here.